subacute denervation, compartment syndrome, early myositis ossificans, rhabdomyolysis and sickle cell crisis. 6 The clinical course of our patient excluded these causes from the diagnosis. The mechanism of edema and fluid retention remains unknown. One possible mechanism is via the inhibition of the PDGF receptor, as this receptor regulates interstitial fluid pressure by regulating interaction between cells in the connective tissue and molecules in the extracellular matrix. 4,7 Inhibition of PDGF receptor on dermal dendrocytes may be the mechanism reponsible for causing the periorbital edema by imatinib. 5 Imatinib also decreases interstitial fluid pressure and increases the capillary-to-interstitium transport rate in subcutaneous tumors in rats by antagonising PDGF-b. 7 The incidence of muscle cramps and myalgia following imatinib therapy is reportedly 49 and 20%, respectively. 3 MRI of effected muscles suggest that the mechanism of these adverse effects may be partly because of intramuscular edema.